Oncology Xagena

Xagena Mappa
Xagena Newsletter

Search results for "Avelumab"

In a phase 1b trial, Avelumab ( Bavencio ) plus Axitinib ( Inlyta ) as first-line had encouraging antitumor activity for patients with advanced renal cell carcinoma ( aRCC ) ( Lancet Oncol 2018;19:451 ...

Patients with advanced B3 thymoma ( B3T ) and thymic carcinoma ( TC ) resistant to chemotherapy have limited treatment options. Treatment with anti-PD1 showed not negligible toxicity and limited act ...

Despite the broad activity of checkpoint inhibitors across tumor types, primary or secondary resistance after initial response represents a major challenge. Tomivosertib, a potent and highly selec ...